Navigation Links
Kymab Announces Launch of Kymouse HK
Date:9/18/2012

CAMBRIDGE, England, September 18, 2012 /PRNewswire/ --

First human antibody strain from its advanced discovery platform

Kymab, a monoclonal antibody biopharmaceutical company, announced today the launch of Kymouse HK, the first strain from the innovative Kymouse™ antibody discovery platform, which enables rapid discovery of high affinity antibody drug candidates.

Kymouse HK is a transgenic mouse that has been designed to produce a diverse repertoire of high affinity fully human heavy/kappa chain antibodies to a broad range of drug targets. This represents a significant advance over existing commercial strains that are currently used in the pharmaceutical industry.

Kymouse is an antibody discovery platform that has been designed to surpass the diversity of antibodies produced in humans. The platform provides unique tools to discover functional and developable drug candidates to address challenging drug targets. The platform is covered by a strong intellectual property portfolio, including a European Patent (EP2421357) that has received notice of allowance from the European Patent Office.

Dr. Allan Bradley, Chief Scientific Officer of Kymab, said: "Our Kymouse HK strain involves targeted insertion of human heavy chain and kappa chain genes into the corresponding mouse genes to ensure their correct regulatory control and usage, without perturbation of non-immunoglobulin gene function. We have demonstrated that Kymouse HK has a normal B-‐cell compartment, produces high antibody titres of all isotypes in response to antigen challenge and affinity matures antibodies in vivo, through normal rearrangement and somatic hypermutation processes."

Andrew Sandham, Chief Executive Officer, said: "We have developed the innovative Kymouse using novel embryonic stem cell and recombineering technologies. We have applied meticulous attention to quality control at every stage. I am delighted that our efforts have been validated through the launch of our first commercial strain. Our strategy is to use Kymouse HK for our own antibody drug discovery projects and to employ a broad partnering approach to make the strain available to pharmaceutical companies for their own discovery programmes."

About Kymab

Kymab is a "platform to product" biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary Kymouse™ transgenic antibody platform.

Kymouse™ has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding that rare drug candidate with best-in-class characteristics.

Founded in 2009, Kymab raised £20m of equity financing in 2010 from the investment division of the Wellcome Trust. It has an experienced management team with a successful track record in drug discovery and development.

For further information, please visit http://www.kymab.com

Contact Kymab:
Andrew Sandham, Chairman and Chief Executive Officer
Tel: +44(0)1223-833301, Email: andrew.sandham@kymab.com

M: Communications
Mary Clark
Tel: +44 207920 2361, Email: kymab@mcomgroup.com

Kymab, Kymouse, Kymouse HK are trademarks of Kymab Limited.



'/>"/>
SOURCE Kymab
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. AMRI Announces Strategic Contract with Knopp Biosciences
2. Ceramic Society announces selection of Ichinose, Lawn and Moskowitz as 2012 Distinguish Life Members
3. Islet Sciences Announces Exclusive License Agreement with the University of California (UCLA) to Commercialize Small Molecules for Islet Expansion
4. Sequenom Announces Participation At Two Upcoming Investor Conferences
5. BioLife Solutions Announces Presentation at IBC Inaugural Cell Therapy Clinical Development Conference
6. Medical Diagnostic Laboratories, L.L.C. Announces a Complimentary Reflex Test to Determine Azithromycin Resistance in Chlamydia Trachomatis
7. Pro Bono Bio Announces the Successful Development of Subcutaneous and Long-Acting Blood Factors VIIa,VIII and IX for the Treatment of Haemophilia
8. Islet Sciences Announces Exclusive License Agreement with Winthrop University Hospital to Commercialize a Beta Cell Loss Measurement Technology in Diabetes
9. Unprecedented Donation by Korean Stem Cell Leader: Dr. Jeong-Chan Ra of RNL Bio announces the donation of 90% of his wealth
10. Medical Marijuana, Inc. Portfolio Company PhytoSPHERE Systems Announces Successful Production of Hemp Harvesting for High Value CBD Oil
11. BIOCOM Announces Endorsement in 52nd Congressional District Race
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, ... microbial test has received AOAC Research Institute approval 061601. , “This is another ... year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel ...
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
(Date:6/23/2016)... ... 2016 , ... In a new case report published today in STEM CELLS ... developed lymphedema after being treated for breast cancer benefitted from an injection of stem ... with this debilitating, frequent side effect of cancer treatment. , Lymphedema refers ...
Breaking Biology Technology:
(Date:6/22/2016)... Md. , June 22, 2016  The American College ... Trade Show Executive Magazine as one of the ... on May 25-27 at the Bellagio in Las ... on the highest percentage of growth in each of the ... of exhibiting companies and number of attendees. The 2015 ACMG ...
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
Breaking Biology News(10 mins):